Abstract

A phase 1A dose-escalation study published in Nature Medicine evaluated FX-909, a first-in-class oral small-molecule inverse agonist of peroxisome proliferator-activated receptor gamma (PPARγ), in 56 patients with advanced solid tumors, including 46 with urothelial carcinoma. The 3+3 dose-escalation design assessed safety, tolerability, pharmacokinetics, and preliminary antitumor activity. Primary endpoint was safety and tolerability, with secondary endpoints including recommended phase 2 dose (RP2D) determination and preliminary efficacy. FX-909 demonstrated acceptable safety with grade 3 or higher adverse events including anemia (26.8%), thrombocytopenia (21.4%), fatigue (10.7%), and hyperglycemia (7.1%). Recommended phase 2 doses of 30 mg and 50 mg daily were established. Objective responses were observed in 17.5% of patients with urothelial carcinoma across all dose levels, with exploratory analyses suggesting enrichment in patients with high PPARγ expression. These findings support continued clinical development of PPARγ inverse agonists in urothelial carcinoma, particularly in biomarker-selected populations.

Introduction

Urothelial carcinoma represents a substantial global health burden, with approximately 656,000 new diagnoses and 234,000 deaths projected worldwide in 2025.¹ Despite recent therapeutic advances including immune checkpoint inhibitors and antibody-drug conjugates, the majority of patients with metastatic disease experience progression, and a notable subset demonstrate primary refractory disease.² This clinical reality underscores the critical need for novel therapeutic approaches that leverage evolving understanding of urothelial carcinoma molecular biology.

Comprehensive molecular profiling has identified distinct molecular subtypes of urothelial carcinoma, with the luminal subtype comprising approximately 65% of advanced cases.³,⁴ This subtype is characterized by elevated expression of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear hormone receptor and transcription factor that serves essential lineage-determining functions in normal urothelial homeostasis and regeneration. Accumulating evidence indicates that aberrant PPARγ activation drives tumorigenesis in luminal urothelial carcinoma, establishing this pathway as a rational therapeutic target.⁵,⁶,⁷

The identification of PPARγ as a master regulator of luminal lineage in urothelial carcinoma has prompted investigation of PPARγ antagonism as a therapeutic strategy. Traditional PPARγ modulators have demonstrated limited clinical efficacy, potentially due to partial agonist properties that fail to achieve complete pathway inhibition. Inverse agonists, which actively suppress basal receptor activity rather than merely blocking ligand binding, represent a novel approach to more comprehensively inhibit PPARγ signaling.

Study Design and Methods

The FX-909-CLINPRO-1 study employed a standard 3+3 dose-escalation design to evaluate FX-909, a first-in-class oral small-molecule PPARγ inverse agonist, in patients with advanced solid tumors. This phase 1A study enrolled 56 patients, including 46 with urothelial carcinoma, across multiple dose cohorts. The study population consisted of patients with histologically confirmed advanced solid tumors who had progressed on standard-of-care therapies or were considered inappropriate candidates for available treatments.

The primary endpoint was safety and tolerability, assessed through comprehensive adverse event monitoring, laboratory evaluations, and dose-limiting toxicity (DLT) determination during the initial treatment cycle. Secondary endpoints included establishment of the recommended phase 2 dose, pharmacokinetic characterization, and preliminary assessment of antitumor activity according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

The dose-escalation schema followed standard 3+3 methodology, with cohorts receiving escalating doses of oral FX-909 administered daily. Dose-limiting toxicities were assessed during the initial 28-day cycle, with expansion cohorts planned at the maximum tolerated dose or recommended phase 2 dose. Tumor assessments were conducted at baseline and every 8 weeks thereafter using radiographic imaging.

Exploratory analyses included evaluation of PPARγ expression in tumor specimens using immunohistochemistry, with correlation to clinical responses. Pharmacokinetic sampling was performed to characterize FX-909 absorption, distribution, and elimination parameters. The study was registered with ClinicalTrials.gov (NCT05929235) and conducted in accordance with Good Clinical Practice guidelines and institutional review board approvals.

Results

FX-909 demonstrated acceptable safety and tolerability across the evaluated dose range. The most frequent grade 3 or higher adverse events were hematologic in nature, including anemia occurring in 15 of 56 patients (26.8%) and thrombocytopenia in 12 patients (21.4%). Non-hematologic grade 3 or higher toxicities included fatigue in 6 patients (10.7%) and hyperglycemia in 4 patients (7.1%). The pattern of adverse events was consistent with the known biology of PPARγ inhibition and previous preclinical predictions.

Based on the safety profile and tolerability data, two dose levels were selected for recommended phase 2 dose optimization: 30 mg and 50 mg administered orally once daily. These doses achieved target drug exposure levels while maintaining acceptable tolerability, though specific pharmacokinetic parameters were not detailed in the published report.

Preliminary efficacy analysis revealed objective responses in 8 of 46 patients with urothelial carcinoma (17.5%) across all dose levels evaluated. The nature of these responses, including complete versus partial responses and duration of response, was not specified in the available data. Disease control rates and progression-free survival metrics were similarly not reported in the initial publication.

Exploratory biomarker analyses suggested that tumor responses were enriched among patients with high PPARγ expression levels, as determined by immunohistochemical staining. This finding supports the mechanistic rationale for PPARγ inverse agonism and suggests potential utility of PPARγ expression as a predictive biomarker for patient selection in future studies.

The safety profile appeared manageable with standard supportive care measures, and no treatment-related deaths were reported. The frequency of treatment discontinuations due to adverse events was not specified, though the continuation to recommended phase 2 dose determination suggests acceptable tolerability in the majority of patients.

Discussion

The results of this phase 1 study represent an important milestone in the clinical development of PPARγ-targeted therapies for urothelial carcinoma. The 17.5% objective response rate observed in heavily pretreated patients with advanced disease compares favorably to historical controls and suggests meaningful clinical activity. However, interpretation of these preliminary efficacy data requires careful consideration of the study’s inherent limitations and the selected patient population.

The safety profile of FX-909 aligns with anticipated on-target effects of PPARγ inhibition. Hematologic toxicities, particularly anemia and thrombocytopenia, likely reflect PPARγ’s role in hematopoietic regulation. The occurrence of hyperglycemia is consistent with PPARγ’s established function in glucose homeostasis and insulin sensitivity. These toxicities appear manageable with standard supportive care measures, though long-term safety evaluation will require extended follow-up in larger patient cohorts.

The enrichment of responses among patients with high PPARγ expression represents a particularly noteworthy finding that may inform future development strategies. This correlation supports the mechanistic hypothesis underlying PPARγ inverse agonism and suggests potential for biomarker-driven patient selection. However, the threshold for “high” expression and standardization of PPARγ assessment methodology require further validation.

The molecular rationale for targeting PPARγ in luminal urothelial carcinoma is well-established through preclinical investigations. PPARγ activation promotes epithelial differentiation programs that may contribute to therapy resistance, while its inhibition can restore sensitivity to conventional treatments. The clinical translation of this concept through FX-909 represents a notable advancement in precision medicine approaches for urothelial carcinoma.

Comparison to existing therapeutic options for advanced urothelial carcinoma provides additional context for these findings. Contemporary immunotherapy regimens achieve objective response rates of 15-25% in the second-line setting, while antibody-drug conjugates demonstrate responses in 30-40% of patients. The 17.5% response rate with FX-909 monotherapy in this heavily pretreated population suggests potential clinical utility, particularly if responses prove durable.

Limitations

Several limitations merit consideration in interpreting these preliminary results. The phase 1 study design prioritizes safety assessment over efficacy evaluation, limiting the statistical power for response rate determination. The heterogeneous patient population, variable prior treatments, and small sample size preclude definitive efficacy conclusions. Response duration, progression-free survival, and overall survival data were not reported, representing critical gaps for clinical decision-making.

The biomarker analysis remains exploratory, with undefined thresholds for PPARγ expression and potential selection bias in analyzed specimens. Standardization of PPARγ assessment methodology and validation in larger cohorts will be essential for clinical implementation. Additionally, the study enrolled patients across multiple solid tumor types, though the focus on urothelial carcinoma provides the most relevant data for this indication.

Clinical Implications

The preliminary clinical activity of FX-909 in urothelial carcinoma has several important implications for clinical practice and future research directions. Most immediately, these results support advancement to phase 2 development, with particular emphasis on biomarker-selected populations based on PPARγ expression status.

For practicing oncologists, these findings highlight the evolving landscape of targeted therapies in urothelial carcinoma and the potential for molecular subtype-directed treatment selection. While FX-909 remains investigational, the concept of PPARγ inverse agonism may inform treatment sequencing decisions and combination therapy development strategies.

The acceptable safety profile suggests potential for combination approaches with existing standard-of-care treatments. Rational combinations might include immune checkpoint inhibitors, antibody-drug conjugates, or conventional chemotherapy regimens. The mechanism of action suggests potential for non-overlapping toxicities with many current therapies, though formal combination studies will be required to establish safety and efficacy.

From a health systems perspective, the development of PPARγ-targeted therapies may necessitate implementation of companion diagnostic testing for PPARγ expression. Healthcare institutions, including those in Hawaii such as the John A. Burns School of Medicine and Queen’s Medical Center, should anticipate potential requirements for specialized pathology services and molecular testing capabilities.

Patient selection strategies will likely require integration of PPARγ expression status with existing molecular classifications of urothelial carcinoma. This approach aligns with broader trends toward precision medicine in oncology and may improve therapeutic outcomes while reducing unnecessary treatment-related toxicities.

The global burden of urothelial carcinoma, including significant incidence in Pacific Islander populations served by Hawaii’s healthcare system, underscores the importance of expanding therapeutic options. Novel agents like FX-909 may provide particular benefit for patients with limited access to complex multi-agent regimens or those unsuitable for intensive combination therapies.

Future research priorities should include randomized controlled trials comparing FX-909 to standard-of-care treatments, investigation of optimal combination strategies, and validation of PPARγ as a predictive biomarker. Long-term follow-up data regarding response durability and overall survival will be critical for regulatory approval and clinical adoption.

The development of oral targeted agents like FX-909 may also improve treatment accessibility and patient quality of life compared to intravenous therapies requiring frequent healthcare facility visits. This consideration is particularly relevant for patients in geographically dispersed healthcare systems, including those served by Hawaii’s neighbor island medical facilities.

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834

2. Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244-258. doi:10.1016/j.annonc.2021.11.012

3. Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556.e25. doi:10.1016/j.cell.2017.09.007

4. Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420-433. doi:10.1016/j.eururo.2019.09.006

5. Goldstein JT, Berger AC, Shih J, et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 2021;81(24):6162-6179. doi:10.1158/0008-5472.CAN-21-0829